Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the H.C. Wainwright 1st Annual Hereditary Angioedema Virtual Conference on July 20, 2022, at 10:00 a.m. ET. The presentation is accessible via a live audio webcast on the company’s website.

BioCryst focuses on developing oral medicines for rare diseases. Their approved product ORLADEYO (berotralstat) is already available in the U.S. and globally. The company is also advancing several programs, including BCX9930 and galidesivir.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced promising long-term efficacy and safety results for ORLADEYO (berotralstat) in treating hereditary angioedema (HAE). Data from the APeX-2 and APeX-S clinical trials highlight sustained reductions in HAE attack rates and improved quality of life. Notably, patients switching from injectable therapies reported 98 percent attack-free days. Presenting at the EAACI Congress 2022, these findings bolster ORLADEYO's position as a preferred oral prophylactic therapy for HAE.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that it will present data at the EAACI Hybrid Congress 2022 in Prague from July 1-3. Key abstract presentations include:

• Attack-free Status: Patients switching from Lanadelumab to Berotralstat.
• Quality of Life Improvement: Observed in long-term Berotralstat treatment.
• Decreased Injectable Medication Use: After 96 weeks of Berotralstat treatment.

ORLADEYO (berotralstat) is designed to prevent hereditary angioedema attacks in patients aged 12 and older.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has formed an exclusive partnership with Pint Pharma GmbH to promote ORLADEYO^® (berotralstat) across the pan-Latin America (LATAM) region. This agreement aims to address the needs of hereditary angioedema (HAE) patients seeking new treatment options. Pint Pharma will handle marketing authorizations and commercialization in LATAM. ORLADEYO, the only oral therapy for HAE prevention, has been successful in several global markets, indicating strong potential for market acceptance in the LATAM region.

BioCryst Pharmaceuticals (BCRX) announced FDA has granted Fast Track designation for BCX9250 aimed at preventing heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) patients. This designation expedites drug development and review for serious conditions with unmet medical needs. BCX9250 targets the ALK-2 enzyme, crucial for FOP, with positive Phase 1 trial results indicating good safety and tolerability. This follows recent PRIME eligibility from EMA, reflecting significant progress in the drug’s development, addressing a critical need in an ultra-rare disease community.

BioCryst Pharmaceuticals (BCRX) announced that Swissmedic has authorized the marketing of ORLADEYO (berotralstat) for preventing recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older in Switzerland. The drug is the first oral, non-steroidal therapy for HAE, enhancing treatment options. Following its European approval last year, BioCryst anticipates launching ORLADEYO in Switzerland after finalizing reimbursement plans. Clinical trials reported gastrointestinal issues which were generally mild and self-resolving.

BioCryst Pharmaceuticals (BCRX) announced the approval of ORLADEYO (berotralstat) by Health Canada for the prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older. This marks a significant advancement for the Canadian HAE community, offering a much-needed oral prophylactic therapy. ORLADEYO is already approved in multiple global markets, and the company is committed to ensuring timely access for Canadian patients. Clinical trials reported that ORLADEYO was generally well tolerated, with gastrointestinal reactions being the most common adverse effects.

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at two upcoming healthcare conferences: the Jefferies Healthcare Conference on June 8, 2022, at 9:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 15, 2022, at 12:00 p.m. ET. Investors can access live audio webcasts and replays of these events via the Investors & Media section of BioCryst's website. The company specializes in developing oral small-molecule medicines for rare diseases, with drugs like ORLADEYO® approved in multiple regions, and several ongoing development programs including BCX9930 and galidesivir.

BioCryst Pharmaceuticals (BCRX) announced its participation in several key investor conferences. The company will present at the Bank of America Securities 2022 Healthcare Conference on May 10 at 11:00 a.m. ET in Las Vegas, and at the RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 p.m. ET in New York. Additionally, a pre-recorded fireside chat at the H.C. Wainwright Global Investment Conference will be accessible starting May 24 at 7:00 a.m. ET. Live webcasts will be available on BioCryst's investor relations website.